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Background: In HIV-1 infected patients, production of interleukin-10 (IL-10), a highly immunosuppressive cytokine,
is associated with progression of infection toward AIDS. HIV-1 Tat protein, by interacting with TLR4-MD2 at the
membrane level, induces IL-10 production by primary human monocytes and macrophages. In the present study
we evaluated the effect of the TLR4 antagonist Eritoran tetrasodium (E5564) on HIV-1 Tat-induced IL-10 production.
Findings: Here, we confirm that the recombinant HIV-1 Tat protein and the GST-Tat 1–45 fusion protein efficiently
stimulate IL-10 production by primary monocytes and macrophages and that this stimulation is inhibited by
blocking anti-TLR4 mAbs. We show that a similar inhibition is observed by preincubating the cells with the
TLR4 antagonist E5564.
Conclusion: This study provides compelling data showing for the first time that the TLR4 antagonist E5564
inhibits the immunosuppressive cytokine IL-10 production by primary human monocytes and macrophages
incubated in the presence of HIV-1 Tat protein.
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In HIV-1 infected patients, the deregulation of the immune
system precedes the decline of the T CD4+ lymphocytes
population. This immune disorder is mainly associated
with the loss of T-cell proliferation in response to stimulat-
ing antigens and with a shift from Th1 to Th2 cytokines
profile, leading to high levels of circulating TNF-α, IL-1,
IL-4, IL-6, IL-12. This deregulation is accompanied by an
enhanced secretion of IL-10 [1-5], an immunosuppressive
cytokine crucial for the global immune dysfunction oc-
curring during the course of HIV-1 infection [6]. Indeed,
peripheral blood mononuclear cells (PBMCs) from HIV-
1-positive patients produce high levels of IL-10, whose
level increases as the patient progresses toward AIDS.
In addition to its role in viral gene expression, the
HIV-1 Tat transactivating protein plays a key role in
the dysregulation of the host immune system. Tat is
secreted by infected cells and detected at the nM level in
the serum of HIV-1 positive patients [7-9]. This cell-free* Correspondence: nathalie.chazal@cpbs.cnrs.fr
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not they are infected, leading to the modulation of cellular
genes expression. In this field, HIV-1 Tat, by acting at the
cell membrane surface, stimulates IL-10 and TNF-α secre-
tion by human monocytes and macrophages [10,11].
Different domains in the HIV-1 Tat protein have been
implicated in interactions with various cell receptors:
(1) the N-terminal region in Tat binds the CD26 recep-
tor expressed at the lymphocyte cell membrane; (2) the
tripeptide RGD (Arginine-Glycine-Aspartate) motif in-
teracts with αvβ3 and α5β1 integrins at the surface of
dendritic cells; (3) the basic region recruits membrane
lipids and the VEGF receptor expressed by endothelial
cells [12]; (4), Albini et al. reported the interaction of
the cysteine-rich region in Tat (24–51) with CCR2, CCR3
and CXCR4 chemokines receptors [13]. Due to this last
property, Tat was proposed to compete with infection by
X4-tropic HIV strains; (5). More recently, we reported that
Tat N-terminal domain, by interacting with the Toll-like
receptor 4-myeloid differentiation factor 2 complexes
(TLR4-MD2), promotes TNF-α and IL-10 secretion by
macrophages and monocytes [14]. Given the crucial im-
portance of IL-10 in immune dysfunction and the capacity
of IL-10 to synergize with inflammatory cytokines toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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inhibition of Tat/TLR4-MD2 may represent in the long
term an attractive therapeutic strategy.
TLR4 antagonists include molecules such as Eritoran
tetrasodium (E5564) and its predecessors (E5531) [15],
Resatorvid (TAK 242, a small molecule inhibitor of TLR4-
CD14 mediated intracellular signaling), and antibodies
targeting the TLR4 receptor. Of note, some therapeutic
agents such as ketamine, opioids and statins may also
non-selectively interfere with TLR4 [16-18]. E5564 is a
structural analog of the A lipid from R sphaeroides
(RsLA), originally synthesized at the Eisai Research
Institute of Boston (Andover, MA) [19]. E5564 competi-
tively binds to TLR4-MD2, prevents LPS-induced NF-κB
activation, inhibits TNF-α, IL-1β, IL-6 and IL-10 release
in vitro and in vivo, and abolishes inflammatory responses
in animal and human models of endotoxemia [15] without
significant intrinsic agonistic effects.
According to these properties, the present study was
designed to evaluate the capacity of E5564 to inhibit
Tat-induced IL-10 production by human monocytes and
macrophages. First, we determined the optimal monocytes
culture conditions required for inhibition of LPS-induced
secretion of IL-10 by E5564. PBMCs were isolated from
buffy coats from HIV-negative donors by Ficoll dens-
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Figure 1 E5564 inhibits LPS-induced production of IL-10 by primary h
anti-TLR4 blocking antibodies (1 μg/ml), or with placebo (10 nM) or with E
(1, 2, 5 ng/ml). The data represent means concentrations of IL-10 in cultureresuspended in 60/30 complete medium (60% AIM V
and 30% Iscove (Gibco) containing penicillin (100 IU/ml),
streptomycin (100 μg/ml) and 10% FCS and cultured for
24 h at 37°C in 5% CO2 (10
6 cells/well) in 24-well Primaria
(Becton Dickinson) tissue culture plates for 24 hours at
37°C in 5% CO2 in order to separate monocytes by plas-
tic adherence. Non-adherent cells were removed, the
remaining cells were washed twice and then stimulated
by increasing concentrations of LPS either directly or
after preincubation with 1 μg/ml HTA125 anti-TLR4
blocking monoclonal antibody (mAb) (eBioscience), or
with 10 nM placebo or with 10 nM E5564 (placebo and
E5564 were kindly provided by Eisai Research Institute
of Boston). Used at these concentrations E5564 and pla-
cebo displayed no cytotoxic effect (data not shown) [20].
After 24 h in culture, supernatants were collected and an-
alyzed for human IL-10 content (ELISA kit, BD Biosci-
ences). In our hands, 10 nM E5564 were effective at
reducing IL-10 production to background levels following
stimulation with 1 to 2 ng/ml LPS. No inhibition was ob-
served when LPS stimulation was performed in the pres-
ence of placebo (Figure 1). Notably, this inhibition was
more efficiently achieved using the E5564 molecule than
the anti-TLR4 mAbs.
Next, we determined in vitro effects of the HIV-1 Tat
protein on IL-10 production by human monocytes.LPS
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uman monocytes. Primary human monocytes were treated or not by
5564 (10 nM) before stimulation by increasing concentration of LPS
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Figure 2 HIV-1 Tat-induced IL-10 secretion by monocytes is TLR4-dependent. Monocytes pre-incubated or not with blocking antibodies
against TLR4 (1 μg/ml) or isotype-matched mAb were treated with HIV-1 Tat protein (10 nM), GST-Tat 1–45 (10 nM) or GST (10 nM) as control.
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Figure 3 E5564 counteracts HIV-1-Tat- and GST-Tat 1-45-induced secretion of IL-10 by human monocytes. Primary human monocytes
were preincubated or not with E5564 (10 nM) or placebo (10 nM) before stimulation by HIV-1 Tat protein (10 nM), GST-Tat 1–45 (10 nM) or GST
(10 nM) as a control. The data represent means ± SD of three independent experiments.
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the Agence Nationale de la Recherche sur le SIDA,
Paris, France) or recombinant GST-Tat 1–45 produced
from our laboratory as previously described [21] and
controlled for endotoxin contamination using the Limulus
amebocyte lysate (LAL) assay (Bio-Sepra, France) [10,21-23]
were added to primary human monocytes pre-incubated or
not of with the HTA125 anti-TLR4 mAb or with a non-
specific isotype-matched IgG (1 μg/ml). The supernatant
was collected 24 h post-stimulation and analyzed for hu-
man IL-10 content as previously described [21]. Using this
approach, we showed that stimulation with recombinant
Tat protein or recombinant GST-Tat 1–45 equally stim-
ulated IL-10 production (Figure 2). In contrast, we
found that anti-TLR4 antibodies dramatically decreased
both Tat and GST-Tat 1-45-induced cytokine release.
No inhibition was observed when Tat or GST Tat-145
stimulation was performed in the presence of irrelevant
















Figure 4 E5564 inhibits the release of IL-10 immunosuppressive cytokine
Primary human macrophages were left untreated or preincubated with
non-specific mAb or E5564 (10 nM) or placebo (10 nM) before stimulation by
independent experiments.We next evaluated the consequences of E5564 treat-
ment on IL-10 production by monocytes stimulated with
recombinant Tat or GST-Tat 1–45. We found that 10
nM of E5564 were effective at counteracting the stimu-
lating effects of recombinant Tat or recombinant GST-
Tat 1–45. This effect was not observed when the cells
were incubated with the same concentration of placebo
(Figure 3). According to this observation, E5564 was
effective at inhibiting Tat-induced IL-10 secretion by
monocytes. Finally, these experiments were repeated using
primary human macrophages as target cells. Monocytes
prepared from PBMCs by plastic adhesion were differenti-
ated into macrophages by incubation in a 10% FCS, 1%
M-CSF and 1% PS mixture. Blood monocytes adhered
to plastic after 1 h and acquired macrophage-like morph-
ology within 5 days. On day 7, differentiated macrophages
were stimulated with the recombinant HIV-1 Tat protein
in presence of anti-TLR4 mAb, or irrevelant isotype





Tat +  TLR4
Control 
promoted by the HIV-1 Tat protein in primary human macrophages.
anti-TLR4 blocking antibodies (1 μg/ml) or isotype-matched
the HIV-1 Tat protein (10 nM). The data represent means ± SD of three
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production. No inhibition was observed when macrophages
were incubated with the placebo molecule or with the
isotype-matched non-specific mAb (Figure 4).
Altogether, these results indicate that the TLR4 agonist
E5564 inhibits Tat-induced secretion of IL-10, by pri-
mary human monocytes and macrophages. This mol-
ecule was recently shown to represent a novel issue in
therapeutic management of inflammation associated with
influenza infection [24-26] and treatment for sepsis [27].
The powerful immunosuppressive properties of IL-10, the
strong association between elevated serum concentrations
of this immunosuppressive Th2 cytokine with disease
progression in HIV-1-infected patients together with
the capacity of the retroviral Tat protein to stimulate IL-10
release through TLR4 binding strongly supports that inhib-
ition of Tat/TLR4-MD2 interactions may represent a good
candidate to decrypt the mechanisms responsible for IL-10
deregulation in HIV infection. In this respect, E5564 repre-
sents an attractive tool for understanding how HIV infec-
tion induces a state of immunodeficiency.
Statistical tests
All statistical analyses used the Student’s t-test, unpaired
for normal distribution, for at least three independent
experiments. Differences were considered significant at
p values < 0.05. Microsoft Excel and Prism were used to
construct the plots and measure means, standard devia-
tions and p values.
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